Ocular tolerance of absorption enhancers in ophthalmic preparations

被引:3
|
作者
Furrer, P [1 ]
Mayer, JM
Plazonnet, B
Gurny, R
机构
[1] Univ Geneva, Dept Pharmaceut & Biopharmaceut, Sch Pharm, CH-1211 Geneva 4, Switzerland
[2] Univ Lausanne, Sch Pharm, Inst Med Chem, CH-1015 Lausanne, Switzerland
[3] Merck Sharp & Dohme Ltd, Ctr Rech, F-63203 Riom, France
来源
AAPS PHARMSCI | 2002年 / 4卷 / 01期
关键词
ocular absorption; permeation enhancers; confocal microscopy; toxicity;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The use of absorption promoters is a way to improve the bioavailability and therapeutic response of topically applied ophthalmic drugs. The ocular tolerance of 9 potential absorption promoters was investigated as well as the influence of the enhancers' concentration on the ocular tolerance. The substances tested were instillated repetitively (4 times per day, during 3 days, and once just before examination) as aqueous solutions onto rabbit corneas. Fluorescein dyeing enabled us to specifically mark corneal damage that was observed by confocal microscopy. The degree of corneal injury was assessed with an image-processing system that calculated the total fluorescent areas. Confocal microscopy results showed the relatively good tolerance of permeation enhancers like dimethyl sulfoxide (DMSO), decamethonium, edetate, glycocholate, and cholate in contrast to the poorly tolerated saponin and fusidate. Increasing the promoters' concentration led generally to an increase in corneal lesions.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Ocular tolerance of absorption enhancers in ophthalmic preparations
    Furrer P.
    Mayer J.M.
    Plazonnet B.
    Gurny R.
    AAPS PharmSci, 4 (1):
  • [2] Isolated preparations of ocular vasculature and their applications in ophthalmic research
    Yu, DY
    Su, EN
    Cringle, SJ
    Yu, PK
    PROGRESS IN RETINAL AND EYE RESEARCH, 2003, 22 (02) : 135 - 169
  • [3] Penetration enhancers and ocular bioadhesives: Two new avenues for ophthalmic drug delivery
    Kaur, IP
    Smitha, R
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2002, 28 (04) : 353 - 369
  • [4] Bioavailability and ocular disposition of ketorolac tromethamine from various ophthalmic preparations
    El-Aleem, Hamdy M. Abd
    Sakr, Farouk M.
    Soliman, Osama A.
    Hatem, El Awady
    Salama, Germeen N.
    BULLETIN OF PHARMACEUTICAL SCIENCES, 2007, 30 : 275 - 297
  • [5] Recent advances in ophthalmic preparations: Ocular barriers, dosage forms and routes of administration
    Maulvi, Furqan A.
    Shetty, Kiran H.
    Desai, Ditixa T.
    Shah, Dinesh O.
    Willcox, Mark D. P.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 608
  • [6] Unorthodox ophthalmic preparations on the Ghanaian market: a potential risk for ocular and enteric infections
    Kyei, Samuel
    Dogbadze, Eric
    Tagoh, Selassie
    Mwanza, Estele
    AFRICAN HEALTH SCIENCES, 2020, 20 (01) : 515 - 523
  • [7] TERATOLOGICAL EVALUATION OF OPHTHALMIC PREPARATIONS BY OCULAR, DERMAL, AND INTRAPERITONEAL ROUTES OF ADMINISTRATION IN RABBIT
    SZABO, KT
    PALMER, AK
    TERATOLOGY, 1974, 9 (03) : A38 - A39
  • [8] THE EFFECT OF PILOCARPINE ON OCULAR LEVOBUNOLOL ABSORPTION FROM OPHTHALMIC SOLUTIONS
    TANGLIU, DDS
    RICHMAN, JB
    JOURNAL OF OCULAR PHARMACOLOGY, 1994, 10 (04): : 605 - 615
  • [9] OPHTHALMIC PRESERVATIVES AS ABSORPTION PROMOTERS FOR OCULAR DRUG-DELIVERY
    SASAKI, H
    NAGANO, T
    YAMAMURA, K
    NISHIDA, K
    NAKAMURA, J
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (09) : 703 - 707
  • [10] RELATIVE OCULAR TOLERANCE OF OPHTHALMIC SOLUTIONS OF TIMOLOL AND BETAXOLOL IN NORMAL VOLUNTEERS
    RYAN, M
    JAIN, AK
    RYAN, JR
    MCMAHON, FG
    RICHARDS, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (02) : 193 - 193